Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197.
Marketing Status Prescription; Discontinued
ATC Code C09CA06
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-640; 0378-3224; 62559-643; 62332-341; 49884-659; 0378-3225; 72761-002; 49884-660; 62559-641; 63629-2127; 46708-342; 49884-661; 0378-3232; 68382-191; 70771-1204; 63629-2126; 17228-0032; 62332-342; 70518-2719; 0378-3231; 60687-119; 62332-343; 46708-060; 70771-1207; 60687-241; 70771-1205; 68382-190; 17228-0017; 46708-343; 68382-192; 62559-642; 68382-193; 49884-658; 62332-060; 46708-877; 70771-1206; 17228-0016; 17228-0018; 70518-2884; 64220-114; 60687-130; 46708-341; 52562-100; 65372-1128
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.0030.017347%
Hypertension24.08.02.0010.048185%
Hypertensive crisis24.08.01.0010.015419%Not Available
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypertriglyceridaemia14.08.02.001--
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.0230.009637%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.009637%
Hypokalaemia14.05.03.0020.009637%
Hyponatraemia14.05.04.0020.038548%
Hypotension24.06.03.0020.044330%
Hypothyroidism14.11.01.012; 05.02.03.0010.005782%
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.0010.009637%Not Available
Influenza like illness08.01.03.0100.003855%
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Insulin autoimmune syndrome05.06.01.007; 14.06.01.007; 10.04.08.0050.003855%Not Available
Intentional self-injury19.12.01.002; 12.01.08.0360.003855%Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.005782%Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.005782%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint contracture15.01.08.0010.001508%Not Available
Joint swelling15.01.02.0040.009637%Not Available
Laryngitis22.07.03.001; 11.01.13.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.005782%
Leukopenia01.02.02.001--Not Available
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.005782%Not Available
Lipase increased13.05.01.0030.003855%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 15 Pages